Search News
-
Published on 04:24 GMTSource: Business Standard - Center-right
-
Published on Sep 19, 2024
Axcelead Drug Discovery Partners and Eli Lilly enter collaboration
Source: BioWorld - Label Pending -
Published on Sep 18, 2024
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Counter Cyclical and Defensive Stock to Invest In
We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other counter cyclical and defensive stocks to invest …
Source: Insider Monkey - Neutral -
Published on Sep 18, 2024
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. Goldman Sachs projects that the anti-obesity market will be worth as much as $100 billion by the end of the decade. It's currently dominated by a few big …
Source: myMotherLode - Label Pending -
Published on Sep 17, 2024
Eli Lilly's eczema drug receives FDA approval one year after its initial rejection from BioPharma-Reporter.com
The FDA has granted Eli Lilly approval for Ebglyss (lebrikizumab-lbkz) for the treatment of moderate-to-severe atopic dermatitis, also commonly known as eczema. The drug is intended for patients whose condition cannot be controlled well with topical …
Source: Outsourcing-Pharma - Label Pending -
Published on Sep 17, 2024
ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC
On 15 September 15 2024 results for the Phase III SPLASH trial were presented at the European Society of Medical Oncology (ESMO) Congress 2024. The trial compares Eli Lilly’s lutetium zadavotide guraxetan (177Lu-PNT2002) with the androgen receptor pathway …
Source: Clinical Trials Arena - Label Pending -
Published on Sep 17, 2024
Eli Lilly invests US$1bn in ongoing Irish expansion
JHVEPhoto / Shutterstock.com AMERICAN pharmaceutical company Eli Lilly has invested US$1bn into the expansion of its manufacturing site in Limerick, Ireland, increasing the production of vital medicines for treating Alzheimer’s. The company’s new …
Source: The Chemical Engineer - Label Pending -
Published on Sep 18, 2024
FDA approves Lilly’s EBGLYSS for adults and children 12 years and older with moderate-to-severe atopic dermatitis
The U.S. Food and Drug Administration (FDA) has approved Eli Lilly and Company’s EBGLYSS (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate- …
Source: Pharma Business International - Neutral -
Published on Sep 17, 2024
Eli Lilly's Eczema Drug Gets FDA Approval, Injectable Treatment Available Within Weeks
The U.S. Food and Drug Administration has approved Eli Lilly's eczema drug, providing a new treatment option for people with moderate-to-severe atopic dermatitis that does not respond to topical prescriptions. Atopic dermatitis is a common form of …
Source: Medical Daily - Uncategorized -
Published on Sep 16, 2024
FDA approves new eczema drug from Eli Lilly for kids, adults
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older. The medication is an injectable branded Ebglyss and will be available in the next few weeks, the company said. Eczema, also …
Source: USA Today - Neutral